Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levetiracetam low-dose - AgeneBio

Next Previous
X
Search
Drug Profile

Levetiracetam low-dose - AgeneBio

Alternative Names: AGB-101; Low-dose levetiracetam - AgeneBio

Latest Information Update: 06 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer AgeneBio
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Mild cognitive impairment
  • Phase II Parkinson's disease

Most Recent Events

  • 03 Dec 2024 AngeneBio initiates a phase III trial in Mild cognitive impairment in USA (PO) (NCT05986721)
  • 14 Sep 2023 Phase-II clinical trials in Parkinson's disease (In adults, In the elderly) in USA (PO) (NCT05824728)
  • 14 Aug 2023 AgeneBio plans a phase III trial in Mild cognitive impairment (In adults, In elderly) in Unknown location (PO, Controlled release tablet) in December 2024 (NCT05986721)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top